Aarsland, D, Larsen, JP, Cummins, JL, Laakek, . Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol
1999; 56: 595–601.
Fénelon, G, Mahieux, F, Huon, R, Ziégler, M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain
2000; 123: 733–45.
Aarsland, D, Larsen, JP, Tandberg, E, Laake, K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc
2000; 48: 938–42.
Goetz, CG, Stebbins, GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology
1995; 45: 669–71.
Cummings, JL. Managing psychosis in patients with Parkinson's disease. N Engl J Med
1999; 340: 801–3.
Fernandez, HH, Trieschmann, ME, Burke, MA, Jacques, C, Friedman, JH. Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord
2003; 18: 510–14.
Targum, SD, Abbott, JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol
2000; 20: 54–60.
Aarsland, D, Larsen, JP, Lim, NG, Tandberg, E. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsych Clin Neurosci
1999; 11: 392–94.
Ford, B, Lynch, T, Greene, P. Risperidone in Parkinson's disease. Lancet
1994; 344: 681.
Meco, G, Alessandri, A, Giustini, P, Bonifati, V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord
1997; 12: 610–12.
Friedman, JH, Factor, SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord
2000; 15: 201–11.
Fernandez, HH, Aarsland, D, Fénelon, G, Friedman, JH, Marsh, L, Tröster, AI, et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord
2008; 23: 484–500.
Higgins, JP, Altman, DG, Gøtzsche, PC, Jüni, P, Moher, D, Oxman, AD, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ
2011; 343: D5928.
Fernandez, HH, Okun, MS, Rodriguez, RL, Malaty, IA, Romrell, J, Sun, A, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci
2009; 119: 2196–205.
Rabey, JM, Prokhorov, T, Miniovitz, A, Dobronevsky, E, Klein, C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord
2007; 22: 313–18.
Shotbolt, P, Samuel, M, Fox, C, David, AS. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsych Dis Treat
2009; 5: 327–32.
Ondo, WG, Tintner, R, Voung, KD, Lai, D, Ringholz, G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord
2005; 20: 958–63.
Pollak, P, Tison, F, Rascol, O, Destée, A, Péré, JJ, Senard, JM, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry
2004; 75: 689–95.
Friedman, . Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson study group. N Engl J Med
1999; 340: 757–63.
Breier, A, Sutton, VK, Feldman, PD, Kadam, DL, Ferchland, I, Wright, P, Friedman, JH. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psych
Ondo, WG, Levy, JK, Vuong, KD, Hunter, C, Jankovic, J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Dis
2002; 17: 1031–35.
Nichols, MJ, Hartlein, JM, Eicken, MGA, Racette, BA, Black, KJ. A fixed-dose randomised controlled trail of olanzapine for psychosis in Parkinson disease. F1000 Res
2014; 2: 150.
Cummings, J, Isaacson, S, Mills, R, Williams, H, Chi-Burns, K, Corbett, A, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet
2014; 383: 533–40.
Rigler, SK, Shireman, TI, Cook-Wiens, GJ, Ellerbeck, EF, Whittle, JC, Mehr, DR, et al. Fracture risk in nursing home residents initiating antipsychotic medications. J Am Geriatr Soc
2013; 61: 715–22.
Citrome, L, Collins, JM, Nordstrom, BL, Rosen, EJ, Baker, R, Nadkarni, A, et al. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics. J Clin Psychiatry
2013; 74: 1199–206.
Leucht, S, Kane, JM, Etschel, E, Kissling, W, Hamann, J, Engel, RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology
2006; 31: 2318–25.
NICE. Parkinson's Disease: Diagnosis and Management in Primary and Secondary Care
. NICE, 2006.
Wolters, EC, Hurwitz, TA, Mak, E, Teal, P, Peppard, FR, Remick, R, et al. Clozapine in the treatment of Parkinsonian patients with dopaminomimetic psychosis. Neurology
1990; 40: 832–34.
Ballanger, B, Strafella, AP, van Eimeren, T. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol
2010; 67: 416–21.
Hack, N, Fayad, SM, Monari, EH, Akbar, U, Hardwick, A, Rodriguez, RL, et al. An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. PLoS One
2014; 9: E91545.
Shulman, LM, Gruber-Baldini, AL, Anderson, KE, Fishman, PS, Reich, SG, Weiner, WJ. The clinically important difference on the unified Parkinson's disease rating scale. Arch Neurol
2010; 67: 64–70.